NICE National Institute for Health and Care Excellence

NICE guidance

Idelalisib for treating follicular lymphoma that is refractory to 2 prior treatments (terminated appraisal)

Technology appraisal guidance

Published: 17 December 2014
nice.org.uk/guidance/ta328

Contents

Advice

NICE is unable to make a recommendation about the use in the NHS of idelalisib for treating follicular lymphoma that is refractory to 2 prior lines of treatment because no evidence submission was received from Gilead Sciences for the technology.

Background

Gilead Sciences was invited to submit evidence for the single technology appraisal of idelalisib for treating follicular lymphoma that is refractory to 2 prior lines of treatment in July 2014.

The company informed NICE that it would not be making an evidence submission. It stated that the currently available data would not allow for a meaningful and robust submission of evidence for this appraisal and that relevant trials were ongoing. The company stated that it would inform NICE as any significant new evidence becomes available to enable a future submission.

NICE has therefore terminated this single technology appraisal.

Information

NHS organisations should take into account the reasons why the company did not make an evidence submission when considering whether or not to recommend local use of idelalisib for treating follicular lymphoma that is refractory to 2 prior lines of treatment. If, after doing this, organisations still wish to consider idelalisib for treating follicular lymphoma that is refractory to 2 prior lines of treatment, they should follow the advice set out in the NHS Constitution for England and the National Health Service Commissioning Board and Clinical Commissioning Groups (Responsibilities and Standing Rules) Regulations 2012, which outline the approach that should be adopted when NICE guidance is unavailable.

NICE will review the position at any point if the company indicates that it wishes to make a full submission.

ISBN: 978-1-4731-0915-5

Accreditation